Skip to main content
Download PDF

Monocyte to high-density lipoprotein cholesterol ratio is associated with cerebral small vessel diseases

BMC Neurology volume 24, Article number: 18 (2024) Cite this article

Abstract

Background

Inflammation is a major pathological mechanism underlying cerebrovascular disease. Recently, a new inflammatory marker based on the ratio between monocyte count and high-density lipoprotein (HDL) cholesterol has been proposed. In this study, we evaluated the relationship between monocyte-to-HDL cholesterol ratio (MHR) and cerebral small vessel disease (cSVD) lesions in health check-up participants.

Methods

This study was a retrospective cross-sectional study based on a registry that prospectively collected health check-up participants between 2006 and 2013. Three cSVD subtypes were measured on brain magnetic resonance imaging. White matter hyperintensity (WMH) volume, and lacunes and cerebral microbleeds (CMBs) were quantitatively and qualitatively measured, respectively. The MHR was calculated according to the following formula: MHR = monocyte counts (× 103/μL) / HDL cholesterol (mmol/L).

Results

In total, 3,144 participants were evaluated (mean age: 56 years, male sex: 53.9%). In multivariable analyzes adjusting for confounders, MHR was significantly associated with WMH volume [β = 0.099, 95% confidence interval (CI) = 0.025 to 0.174], lacune [adjusted odds ratio (aOR) = 1.43, 95% CI = 1.07–1.91], and CMB (aOR = 1.51, 95% CI = 1.03–2.19). In addition, MHR showed a positive quantitative relationship with cSVD burden across all three subtypes: WMH (P < 0.001), lacunes (P < 0.001), and CMBs (P < 0.001).

Conclusions

High MHR was closely associated with cSVD in health check-up participants. Because these associations appear across all cSVD subtypes, inflammation appears to be a major pathological mechanism in the development of various cSVDs.

Peer Review reports

Background

Cerebral small vessel disease (cSVD) is a subclinical pathology commonly observed in current health examinations due to aging and the development of brain imaging technology [1]. cSVD increases the risk of dementia and stroke, and has received clinical attention [2, 3]. However, unlike those previously known to be asymptomatic, several studies have recently revealed that cSVD itself can cause cognitive impairment, dysphagia, and gait disturbance if the disease burden increases [4]. Therefore, studies have been conducted to identify common pathological mechanisms and risk factors that penetrate various cSVD subtypes [white matter hyperintensity (WMH), lacunes of presumed vascular origin, and cerebral microbleed (CMB)] [5,6,7].

Inflammation is one of these pathological mechanisms underlying the development of cSVD [8]. Chronic inflammation affects large and small cerebral vessels through various mechanisms including endothelial dysfunction, atherosclerosis, and thrombus formation [7, 9]. This phenomenon also occurs in the perforating artery that can cause cSVD; thus, various inflammatory markers are closely related to cSVD [10,11,12]. In particular, recently, novel inflammatory markers created by combining various inflammatory cells or biomarkers in consideration of the underlying pathological mechanism, such as the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, and systemic immune-inflammation index, have also been shown to be closely related to cSVD [13,14,15].

The monocyte-to-high-density lipoprotein (HDL) cholesterol ratio is also one of these novel markers [16]. Monocytes are cells that play an important role in chronic inflammation, and HDL cholesterol has properties that inhibit several functions of monocytes [17, 18]. Therefore, the ratio between them can more clearly reflect the inflammatory function of monocytes. Based on these properties, the monocyte-to-HDL cholesterol ratio (MHR) has been shown to be associated with various metabolic syndromes, atherosclerosis, and cardiovascular and cerebrovascular diseases in several studies [17,18,19,20,21,22,23,24]. However, studies analyzing the association between cSVD, subclinical cerebrovascular disease, and MHR are still lacking [25].

In this study, we evaluated the association between MHR values and radiological lesions of cSVD in health check-up participants. By examining the association between each subtype of cSVD and MHR, we examined whether MHR is a risk factor that applies to all cSVD pathologies or a risk factor that reflects only a specific pathology. We expected that these results would confirm the possibility of MHR in selecting high-risk groups requiring a diagnosis of cSVD. In addition, the potential of MHR as a biomarker for cSVD was evaluated compared with NLR, a well-known inflammatory biomarker.

Methods

Study population

Based on the prospectively collected health check-up registry data from the Seoul National University Hospital Health Promotion Center, we evaluated participants who underwent brain magnetic resonance imaging (MRI) between January 2006 and December 2013 (n = 3,257). As part of a health check-up, this center has been conducting extensive demographic, clinical, laboratory, and radiological evaluations [13]. Among them, the following participants were excluded based on the exclusion criteria: 1) having a history of stroke or severe neurological disease (n = 45), 2) age under 30 years (n = 7), 3) with missing data for major variables (n = 4), 4) history of severe systemic inflammatory conditions (e.g., hemato-oncologic disease, severe hepatic or renal disease, major surgery or trauma, use of immunosuppressant, and active infection within two weeks) (n = 57) [13]. Resultantly, 3,144 health check-up participants were included in the final analyses.

Korean medical services are characterized by high accessibility to brain imaging and relatively reasonable medical costs. Because of this, many people perform brain MRI for health screening purposes even without suspecting neurological disorder. Therefore, the study population of this study can be interpreted as a general population without serious neurological history.

Demographic, clinical, and laboratory findings

We evaluated various demographic and clinical factors including age, sex, body mass index, hypertension, diabetes, hyperlipidemia, ischemic heart disease, current smoking, use of antiplatelet agents, and systolic and diastolic blood pressure (BP) [15].

Laboratory evaluations were performed after overnight fasting or at least 12 h [15]. Laboratory evaluation included hemoglobin A1c (%), fasting glucose (mmol/L), total/low-density lipoprotein (LDL)/HDL cholesterol (mmol/L), triglycerides (mmol/L), white blood cell (WBC) counts (× 103/μL), neutrophil/lymphocyte/monocyte counts (× 103/μL), and high-sensitivity C-reactive protein (hs-CRP) (mg/dL). MHR was calculated by dividing the monocyte count by HDL cholesterol, as follows: MHR = monocyte counts (× 103/μL) / HDL cholesterol (mmol/L). The NLR was calculated as the ratio of neutrophil and lymphocyte counts as follows: NLR = neutrophil counts (× 103/μL) / lymphocyte counts (× 103/μL) [16, 17, 22].

Radiological findings

All participants underwent brain MRI and angiography (MRA) using 1.5-T MR scanners (Signa, GE Healthcare, Milwaukee, WI, USA or Magnetom, SONATA, Siemens, Munich, Germany) on the same day as the other tests. Detailed information about each MRI acquisition was as follows: basic slice thickness = 5 mm, T1-weighted images: repetition time (TR)/echo time (TE) = 500/11 ms, T2-weighted images: TR/TE = 5,000/127 ms, T2 fluid-attenuated inversion recovery images (FLAIR): TR/TE = 8,800/127 ms, T2-gradient echo images: TR/TE = 57/20 ms, and three-dimensional time-of-flight MRA images: TR/TE = 24/3.5 ms, slice thickness = 1.2 mm.

As subtypes of cSVD, we evaluated three pathologies: WMH, lacunes, and CMBs. The volume of WMH was quantitatively measured using Medical Imaging Processing, Analysis, and Visualization software (MIPAV, version, 11.0.0, National Institutes of Health, Bethesda, MD, USA). To accomplish this, each participant’s MRI image was obtained in the form of a DICOM file and then entered into the program for analysis. We specified the boundary line of the WMH lesions observed on T2 FLAIR images for each slice and combined them to calculate the volume in a semi-automated manner [15]. Lacunes were defined as well-defined asymptomatic lesions ranging from 3 to 15 mm in the territories of perforating arterioles with signal characteristics similar to those of cerebrospinal fluid on T1- or T2-weighted images [5]. CMBs were defined as focal round lesions less than 10 mm in size with low signal intensity on T2-gradient echo images [5]. For lacunes and CMBs, disease burden was measured as absent, single, or multiple, according to the number of lesions. All radiological parameters were rated by two neurologists (K.-W.N. and H.-Y.J.). Disagreements were resolved through discussion with a third rater (H.-M.K.).

Statistical analysis

All statistical analyses were performed using SPSS version 23.0 (IBM Corp., Armonk, NY, USA). Continuous variables with normal distributions were presented as the mean ± standard deviation and the others were shown as the median [interquartile range]. Continuous variables with skewed data were transformed to log scales. Exceptionally, only the WMH volume was transformed into a squared-root scale because many participants had a value of zero.

To determine the characteristics of participants with high MHR, we compared the demographic, clinical, laboratory, and radiological findings according to MHR tertiles. The Kruskal–Wallis test, Jonckheere-Terpstra test, and chi-square test were used for this analysis.

To perform univariate analysis, we used simple linear regression analysis for WMH volume. For binary outcomes such as lacunes and CMBs, Student’s t-test, Mann–Whitney U-test, chi-squared test, and Fisher’s exact test were appropriately used according to the characteristics of the variables. Variables with P < 0.05 as a result of univariate analysis were introduced to multivariable linear or logistic regression analyses. Using NLR, another well-known subclinical inflammation marker, we performed sensitivity analyses using the same statistical methods.

We analyzed not only the association but also the quantitative relationship between MHR and cSVD subtypes. The MHR values according to the disease burdens of WMH, lacunes, and CMBs were compared, and the Jonckheere-Terpstra test was used for this analysis. All variables with P < 0.05 were considered significant in this study.

Results

A total of 3,144 participants were evaluated (mean age: 56 ± 9 years, male sex: 53.9%). The mean MHR value was 0.28 ± 0.14 and the mean WMH volume was 2.64 ± 6.36 mL. The prevalence of lacunes and CMBs were 230 (7.3%) and 129 (4.1%), respectively. The other detailed baseline characteristics are presented in Table 1.

Table 1 Baseline characteristics of the cohort (n = 3,144)
Full size table

In comparison between MHR tertiles, as MHR value increased, the frequency of male sex, hypertension, diabetes, and current smoking increased. Additionally, BP was high, and glucose and lipid profiles, cell counts, and inflammatory markers also increased overall. The burden of cSVD lesions also increased as the MHR value increased (Fig. 1). Detailed data can be found in Table 2.

Fig. 1
figure 1

Quantitative relationships between monocyte to HDL cholesterol ratio and each subtype of cerebral small vessel disease. Monocyte to HDL cholesterol ratio showed a positive quantitative association with all types of cerebral small vessel disease, including white matter intensity volume (P < 0.001), lacunes (P < 0.001), and cerebral microbleed (P < 0.001)

Full size image
Table 2 Comparisons of baseline characteristics among the MHR tertiles
Full size table

WMH volume was associated with age, hypertension, diabetes, current smoking, use of antiplatelet agents, systolic and diastolic BP, hemoglobin A1c, fasting glucose, LDL cholesterol, WBC, neutrophil, monocyte counts, NLR, and MHR in univariate linear regression analyses. In the multivariable linear regression analysis, MHR was significantly associated with WMH volume after adjusting for confounders [β = 0.099, 95% confidence interval (CI) = 0.025 to 0.174]. Age (β = 0.050, 95% CI = 0.046 to 0.054), hypertension (β = 0.163, 95% CI = 0.077 to 0.249), diabetes (β = 0.143, 95% CI = 0.002 to 0.284), and systolic BP (β = 0.006, 95% CI = 0.002 to 0.010) were also associated with WMH volume, independent of MHR (Table 3).

Table 3 Univariate and multivariable analyses to evaluate the association between possible predictors and white matter hyperintensity volume
Full size table

In multivariable logistic regression analyses performed according to the results of univariate analyses (Tables S1 and S2), MHR showed a significant association with lacunes [adjusted odds ratio (aOR) = 1.43, 95% CI = 1.07–1.91] and CMB (aOR = 1.51, 95% CI = 1.03–2.19). In addition, lacunes showed a statistically significant association with age (aOR = 1.09, 95% CI = 1.07–1.11) and diastolic BP (aOR = 1.02, 95% CI = 1.00–1.05), while CMB showed a close association with age (aOR = 1.06, 95% CI = 1.04–1.08) and systolic BP (aOR = 1.01, 95% CI = 1.00–1.03, Table 4).

Table 4 Multivariable logistic regression analyses to evaluate the association between possible predictors and lacune/cerebral microbleeds
Full size table

In the sensitivity analysis using NLR instead of MHR, NLR significantly associated with WMH volume (β = 0.156, 95% CI = 0.073 to 0.238). However, NLR was not significantly associated with lacunes (aOR = 1.06, 95% CI = 0.76–1.47) and CMB (aOR = 0.89, 95% CI = 0.58–1.37, Table S3).

Discussion

In this study, a high MHR was associated with cSVD lesions on MRI in health check-up participants. The MHR showed a close association with all subtypes of cSVD, even showing a positive quantitative relationship. Therefore, we demonstrated that inflammation is a common pathological mechanism that induces various cSVD pathologies. Furthermore, MHR performed better as a biomarker than NLR in indicating an association between cSVD and inflammation.

The exact pathological mechanisms that could explain the close association between MHR and cSVD remain unclear. We attempted to infer these mechanisms by considering the characteristics of monocytes and HDL cholesterol, which constitute the MHR. First, monocytes are closely associated with endothelial dysfunction. Monocytes penetrate the subendothelial space through the surface of activated or damaged endothelial cells, differentiate into foam cells, and secrete various inflammatory cytokines (e.g., TNF-a, IL-6, and IL-6) and chemokines [17, 18, 20, 22, 23, 26]. These substances induce focal and systemic inflammation, exacerbate endothelial dysfunction, and can even lead to impairment of the blood–brain-barrier (BBB) [5]. Impaired BBB increases permeability, which can cause periventricular infiltration of several toxic metabolites, resulting in damage to the surrounding nerve tissue [1, 6, 15]. In addition, the clearance of interstitial fluid through the glymphatic pathway can also be disrupted [1, 15]. These mechanisms are sufficient to create and exacerbate cSVD. Second, activated monocytes can induce microvascular and macrovascular atherosclerosis. It is widely known that macrophages and foam cells play key roles in atherogenesis [27]. Atherosclerosis of large vessels formed in this way can induce diffuse hypoperfusion, leading to the formation of WMH or lacunes [5, 28]. In addition, in a previous study conducted on patients with pontine infarction, MHR showed a close association with early neurological deterioration [29]. From these results, monocytes are thought to be also involved in micro-atherosclerosis in the perforating artery that directly induces cSVD. Third, circulating monocytes create a hypercoagulable state by secreting various substances including tissue factors [17, 18, 23, 24]. It can occlude perforating arteries by forming microthrombi, which may be involved in the development of WMH or lacunes [7]. Since this procoagulant effect can be suppressed by HDL cholesterol through p38 activation or phosphoinositide 3-kinase, high MHR may be more closely related to this mechanism [17]. Last, patients with a high MHR tend to be older and have multiple vascular risk factors. Previous studies have also shown that MHR is associated with various metabolic diseases, including hypertension, diabetes, and obesity, each of which is an independent risk factor for cSVD.

HDL cholesterol inhibits monocyte function via various pathways. HDL cholesterol inhibits monocyte progenitor cell proliferation and monocyte activation and prevents monocyte migration by inhibiting the expression of adhesion molecules in endothelial cells [17, 18, 23]. In addition, by transferring peripheral cholesterol to the liver, it inhibits monocyte uptake of oxidized LDL cholesterol [17, 23, 24, 26]. This prevents differentiation into foam cells and consequently prevents the inflammatory cascade from proceeding. In addition, regardless of monocyte, HDL cholesterol acts as an antioxidant by itself or induces NO secretion in endothelial cells to exert a neuroprotective effect [18, 25]. In conclusion, from the point of view of HDL cholesterol, it can be interpreted that high MHR does not prevent low HDL cholesterol from exercising the pathological influence of monocytes described above, and does not perform the function of protecting endothelial cells and nerve cells on its own, resulting in cSVD.

Interestingly, in our data, MHR showed close associations with all cSVD subtypes, whereas NLR only showed an association with WMH volume. We investigated why MHR showed a better association with cSVD, even though NLR is a better-known inflammatory marker than MHR. In previous studies, the NLR showed excellent predictive power for various prognoses in patients with acute ischemic stroke [30,31,32]. When a stroke event occurs, the sympathetic tone rises, and as a result, neutrophils and monocytes are released from the bone marrow into the circulating blood [33]. Meanwhile, as the spleen is suppressed, lymphopenia also occurs [33]. Since this phenomenon appears proportional to stroke burden, NLR could show a close association with various acute ischemic stroke outcomes [32]. However, cSVD is a chronic subclinical disease that does not produce acute stress events that are sufficient to induce lymphopenia. Conversely, monocytes are increased in various chronic stressful environments including obesity, diabetes, and hypertension [26, 34]. Low HDL cholesterol is also an indicator of the chronic metabolic status of lipids and an indicator of inhibition of monocyte function. By combining high monocyte count and low HDL cholesterol, MHR appears to be superior to NLR in reflecting the chronic effects of inflammation on cSVD pathologies.

MHR is an indicator that can be obtained easily, simply, and inexpensively through a simple blood test that is now performed in most health check-ups [17]. In addition, it has been recognized as a stable inflammatory marker and has recently been used for diagnosis and prognosis in various inflammatory, vascular, and metabolic diseases [35,36,37,38,39,40]. This is likely to be the case in the area of cerebrovascular disease as well, and our findings suggest the clinical possibility that high MHR values may be helpful in selecting patients at high risk for cSVD who require brain MRI. Korea has relatively good access to brain MRI, but this will also be helpful in terms of health care efficiency in countries with poor medical environments.

Interpreting our results entails several limitations. First, because this was a retrospective cross-sectional study, we can only suggest an association between MHR and cSVD, but cannot guarantee a causal relationship. Second, we analyzed the association with cSVD using a single MHR value measured on the day of the health check-up. As cSVD is a chronic subclinical pathology, it may develop over many years. Therefore, if we analyze the association between MHR values over several time points and the formation and progression of cSVD, clear relationship can be inferred. Third, we did not measure periventricular and subcortical WMH and deep and lobar CMBs separately. Periventricular and subcortical WMH are known to have somewhat different pathological etiologies, and this is also true for lobar and deep CMB [7]. If these pathologies were classified by location and the association between each pathology and MHR was identified, the influence of inflammation on these pathologies could be clarified more clearly. Fourth, cell counts can be affected by various underlying diseases or drugs. Therefore, we must also consider the impact of various comorbidities that we did not include in our analysis. Last, the study population was relatively young and had few vascular risk factors. Therefore, the influence of accompanying comorbidities may be somewhat underestimated.

Conclusion

In conclusion, MHR is closely related to all cSVD subtypes. Since before, a lot of interest and research has been conducted on the possibility of anti-inflammatory treatment of cerebrovascular disease. We may be able to discover new treatments through research that monitors the effectiveness of anti-inflammatory treatment through multiple MHR measurements and tracks the improvement of cerebrovascular disease. However, these expectations must be verified in follow-up prospective studies.

Availability of data and materials

All data covered in this study are presented in the manuscript and the additional files.

Abbreviations

cSVD:

Cerebral small vessel disease

WMH:

White matter hyperintensity

CMB:

Cerebral microbleed

NLR:

Neutrophil to lymphocyte ratio

HDL:

High-density lipoprotein

MHR:

Monocyte-to-HDL cholesterol ratio

BP:

Blood pressure

LDL:

Low-density lipoprotein

WBC:

White blood cell

hs-CRP:

High-sensitivity C-reactive protein

TR:

Repetition time

TE:

Echo time

FLAIR:

Fluid-attenuated inversion recovery

References

  1. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurology. 2013;12(5):483–97.

    Article  PubMed  Google Scholar 

  2. Ter Telgte A, van Leijsen EM, Wiegertjes K, Klijn CJ, Tuladhar AM, de Leeuw F-E. Cerebral small vessel disease: from a focal to a global perspective. Nat Rev Neurol. 2018;14(7):387–98.

    Article  PubMed  Google Scholar 

  3. Patel B, Markus HS. Magnetic resonance imaging in cerebral small vessel disease and its use as a surrogate disease marker. Int J Stroke. 2011;6(1):47–59.

    Article  PubMed  Google Scholar 

  4. Lee E-J, Kang D-W, Warach S. Silent new brain lesions: innocent bystander or guilty party? Journal of stroke. 2016;18(1):38.

    Article  PubMed  Google Scholar 

  5. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, Lindley RI, T O’Brien J, Barkhof F, Benavente OR. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822–38.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Cuadrado-Godia E, Dwivedi P, Sharma S, Santiago AO, Gonzalez JR, Balcells M, Laird J, Turk M, Suri HS, Nicolaides A. Cerebral small vessel disease: a review focusing on pathophysiology, biomarkers, and machine learning strategies. J Stroke. 2018;20(3):302.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2019;18(7):684–96.

    Article  PubMed  Google Scholar 

  8. Low A, Mak E, Rowe JB, Markus HS, O’Brien JT. Inflammation and cerebral small vessel disease: a systematic review. Ageing Res Rev. 2019;53:100916.

    Article  CAS  PubMed  Google Scholar 

  9. Rosenberg GA. Inflammation and white matter damage in vascular cognitive impairment. Stroke. 2009;40(3_suppl_1):S20–3.

    Article  PubMed  Google Scholar 

  10. Van Dijk E, Prins N, Vermeer S, Vrooman H, Hofman A, Koudstaal P, Breteler M. C-reactive protein and cerebral small-vessel disease: the Rotterdam scan study. Circulation. 2005;112(6):900–5.

    Article  PubMed  Google Scholar 

  11. Kim CK, Lee S-H, Kim BJ, Ryu W-S, Choi SH, Oh B-H, Yoon B-W. Elevated leukocyte count in asymptomatic subjects is associated with a higher risk for cerebral white matter lesions. Clin Neurol Neurosurg. 2011;113(3):177–80.

    Article  PubMed  Google Scholar 

  12. Bath PM, Wardlaw JM. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions. Int J Stroke. 2015;10(4):469–78.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Nam K-W, Kwon H-M, Jeong H-Y, Park J-H, Kim SH, Jeong S-M, Yoo TG, Kim S. High neutrophil to lymphocyte ratio is associated with white matter hyperintensity in a healthy population. J Neurol Sci. 2017;380:128–31.

    Article  PubMed  Google Scholar 

  14. Jiang L, Cai X, Yao D, Jing J, Mei L, Yang Y, Li S, Jin A, Meng X, Li H. Association of inflammatory markers with cerebral small vessel disease in community-based population. J Neuroinflammation. 2022;19(1):106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Nam K-W, Kwon H-M, Jeong H-Y, Park J-H, Kwon H. Systemic immune-inflammation index is associated with white matter hyperintensity volume. Sci Rep. 2022;12(1):7379.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kanbay M, Solak Y, Unal HU, Kurt YG, Gok M, Cetinkaya H, Karaman M, Oguz Y, Eyileten T, Vural A. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol. 2014;46:1619–25.

    Article  CAS  PubMed  Google Scholar 

  17. Ganjali S, Gotto AM Jr, Ruscica M, Atkin SL, Butler AE, Banach M, Sahebkar A. Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases. J Cell Physiol. 2018;233(12):9237–46.

    Article  CAS  PubMed  Google Scholar 

  18. Liu H, Zhan F, Wang Y. Evaluation of monocyte-to-high-density lipoprotein cholesterol ratio and monocyte-to-lymphocyte ratio in ischemic stroke. J Int Med Res. 2020;48(7):0300060520933806.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Xi J, Men S, Nan J, Yang Q, Dong J. The blood monocyte to high density lipoprotein cholesterol ratio (MHR) is a possible marker of carotid artery plaque. Lipids Health Dis. 2022;21(1):1–9.

    Google Scholar 

  20. Jiang M, Yang J, Zou H, Li M, Sun W, Kong X. Monocyte-to-high-density lipoprotein-cholesterol ratio (MHR) and the risk of all-cause and cardiovascular mortality: a nationwide cohort study in the United States. Lipids Health Dis. 2022;21(1):1–10.

    Article  CAS  Google Scholar 

  21. You S, Zhong C, Zheng D, Xu J, Zhang X, Liu H, Zhang Y, Shi J, Huang Z, Cao Y. Monocyte to HDL cholesterol ratio is associated with discharge and 3-month outcome in patients with acute intracerebral hemorrhage. J Neurol Sci. 2017;372:157–61.

    Article  CAS  PubMed  Google Scholar 

  22. Liu H, Liu K, Pei L, Gao Y, Zhao L, Sun S, Wu J, Li Y, Fang H, Song B. Monocyte-to-high-density lipoprotein ratio predicts the outcome of acute ischemic stroke. J Atheroscler Thromb. 2020;27(9):959–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Wang H-Y, Shi W-R, Yi X, Zhou Y-P, Wang Z-Q, Sun Y-X. Assessing the performance of monocyte to high-density lipoprotein ratio for predicting ischemic stroke: insights from a population-based Chinese cohort. Lipids Health Dis. 2019;18(1):1–11.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Li Y, Chen D, Sun L, Chen Z, Quan W. Monocyte/high-density lipoprotein ratio predicts the prognosis of large artery atherosclerosis ischemic stroke. Front Neurol. 2021;12:769217.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Ulusoy EK. Correlations between the monocyte to high-density lipoprotein cholesterol ratio and white matter hyperintensities in migraine. Neurol Res. 2020;42(2):126–32.

    Article  CAS  PubMed  Google Scholar 

  26. Karatas A, Turkmen E, Erdem E, Dugeroglu H, Kaya Y. Monocyte to high-density lipoprotein cholesterol ratio in patients with diabetes mellitus and diabetic nephropathy. Biomark Med. 2018;12(9):953–9.

    Article  CAS  PubMed  Google Scholar 

  27. Libby P, Ridker PM, Hansson GK, AtherothrombosisLTNo. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Nam K-W, Kwon H-M, Jeong H-Y, Park J-H, Kim SH, Jeong S-M, Yoo TG, Kim S. Cerebral white matter hyperintensity is associated with intracranial atherosclerosis in a healthy population. Atherosclerosis. 2017;265:179–83.

    Article  CAS  PubMed  Google Scholar 

  29. Bi X, Liu X, Cheng J. Monocyte to high-density lipoprotein ratio is associated with early neurological deterioration in acute isolated pontine infarction. Front Neurol. 2021;12:678884.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Yu S, Arima H, Bertmar C, Clarke S, Herkes G, Krause M. Neutrophil to lymphocyte ratio and early clinical outcomes in patients with acute ischemic stroke. J Neurol Sci. 2018;387:115–8.

    Article  PubMed  Google Scholar 

  31. Kocaturk O, Besli F, Gungoren F, Kocaturk M, Tanriverdi Z. The relationship among neutrophil to lymphocyte ratio, stroke territory, and 3-month mortality in patients with acute ischemic stroke. Neurol Sci. 2019;40:139–46.

    Article  PubMed  Google Scholar 

  32. Li W, Hou M, Ding Z, Liu X, Shao Y, Li X. Prognostic value of neutrophil-to-lymphocyte ratio in stroke: a systematic review and meta-analysis. Front Neurol. 2021;12:686983.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Faura J, Bustamante A, Miró-Mur F, Montaner J. Stroke-induced immunosuppression: implications for the prevention and prediction of post-stroke infections. J Neuroinflammation. 2021;18(1):1–14.

    Article  Google Scholar 

  34. Devesa A, Lobo-González M, Martínez-Milla J, Oliva B, García-Lunar I, Mastrangelo A, España S, Sanz J, Mendiguren JM, Bueno H. Bone marrow activation in response to metabolic syndrome and early atherosclerosis. Eur Heart J. 2022;43(19):1809–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Wang L, Zhang Y, Yu B, Zhao J, Zhang W, Fan H, Ren Z, Liang B. The monocyte-to-high-density lipoprotein ratio is associated with the occurrence of atrial fibrillation among NAFLD patients: a propensity-matched analysis. Front Endocrinol. 2023;14:1127425.

    Article  Google Scholar 

  36. Lin H, Zhu J, Zheng C, Xu X, Ye S. The correlation between visceral fat/subcutaneous fat area ratio and monocyte/high-density lipoprotein ratio in patients with type 2 diabetes mellitus and albuminuria. J Diabetes Complications. 2023;37:108521.

    Article  CAS  PubMed  Google Scholar 

  37. Yang C, Yang Y, Cao S, Ma Z, Du H, Li J, Dou F, Zhao Y, Li X, Hu X. Kawasaki disease coronary artery lesions prediction with monocyte-to-high-density lipoprotein ratio. Pediatr Res. 2023;94(1):246–51.

    Article  CAS  PubMed  Google Scholar 

  38. Cao J, Hua L, Dong L, Wu Z, Xue G. The value of the monocyte to high-density lipoprotein cholesterol ratio in assessing the severity of knee osteoarthritis: a retrospective single center cohort study. J Inflamm Res. 2023;16:595–604.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Deng Y, Zhou F, Li Q, Guo J, Cai B, Li G, Liu J, Li L, Zheng Q, Chang D. Associations between neutrophil-lymphocyte ratio and monocyte to high-density lipoprotein ratio with left atrial spontaneous echo contrast or thrombus in patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord. 2023;23(1):1–9.

    Article  Google Scholar 

  40. Shi K, Hou J, Zhang Q, Bi Y, Zeng X, Wang X. Neutrophil-to-high-density-lipoprotein-cholesterol ratio and mortality among patients with hepatocellular carcinoma. Front Nutr. 2023;10:1127913.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

None.

Funding

This work was supported by Research Resettlement Fund for the new faculty of Seoul National University (07-2021-14) and academic research fund from the Korean Society of Cardiovascular Disease Prevention (KSCP 2022-01).

Author information

Author notes

  1. Hyung-Min Kwon and Jin-Ho Park contributed equally to this work.

Authors and Affiliations

  1. Department of Neurology, Seoul National University College of Medicine, 101 Daehak-Ro, Jongno-Gu, Seoul, 03080, South Korea

    Ki-Woong Nam, Hyung-Min Kwon & Han-Yeong Jeong

  2. Department of Neurology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, 20 Boramae-Ro 5-Gil, Dongjak-Gu, Seoul, 07061, South Korea

    Ki-Woong Nam & Hyung-Min Kwon

  3. Department of Family Medicine, Seoul National University College of Medicine and Seoul National University Hospital, 101 Daehak-Ro, Jongno-Gu, Seoul, 03080, South Korea

    Jin-Ho Park & Kyungha Min

Authors
  1. Ki-Woong Nam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hyung-Min Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Han-Yeong Jeong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jin-Ho Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kyungha Min
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

K.-W.N. and H.-M.K. designed the study. K.-W.N. H.-Y.J., and KH.M. contributed to data acquisition. K.-W.N. performed statistical analysis. K.-W.N., H.-M.K. and J.-H.P. contributed to the discussion. K.-W.N. drafted the manuscript, and H.-M.K. and J.-H.P. edited the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Hyung-Min Kwon or Jin-Ho Park.

Ethics declarations

Ethics approval and consent to participate

The Institutional Review Board (IRB) of the Seoul National University Hospital approved this study (IRB number: 1502-026-647). The requirement for informed consent was waived by the IRB of the Seoul National University Hospital because of the retrospective study design and use of de-identified information. All experiments were performed in accordance with relevant guidelines and regulations (such as the Declaration of Helsinki).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

Differences of characteristics between patients with and without lacune. Table S2. Differences of characteristics between patients with and without cerebral microbleeds. Table S3. Sensitivity multivariable analyses between neutrophil to lymphocyte ratio and cerebral small vessel diseases.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nam, KW., Kwon, HM., Jeong, HY. et al. Monocyte to high-density lipoprotein cholesterol ratio is associated with cerebral small vessel diseases. BMC Neurol 24, 18 (2024). https://doi.org/10.1186/s12883-023-03524-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12883-023-03524-9

Keywords

BMC Neurology

ISSN: 1471-2377

Contact us